High-resolution structure of HLA-A*0201 in complex with a tumour-specific antigenic peptide encoded by the MAGE-A4 gene - PubMed (original) (raw)
. 2001 Jul 27;310(5):1167-76.
doi: 10.1006/jmbi.2001.4816.
Affiliations
- PMID: 11502003
- DOI: 10.1006/jmbi.2001.4816
High-resolution structure of HLA-A*0201 in complex with a tumour-specific antigenic peptide encoded by the MAGE-A4 gene
R C Hillig et al. J Mol Biol. 2001.
Abstract
The heterotrimeric complex of the human major histocompatibity complex (MHC) molecule HLA-A*0201, beta2-microglobulin and the decameric peptide GVYDGREHTV derived from the melanoma antigen (MAGE-A4 protein has been determined by X-ray crystallography at 1.4 A resolution. MAGE-A4 belongs to a family of genes that are specifically expressed in a variety of tumours. MAGE-A4-derived peptides are presented by MHC molecules at the cell surface to cytotoxic T-lymphocytes. As the HLA-A*0201:MAGE-A4 complex occurs only on tumour cells, it is considered to be an appropriate target for immunotherapy. The structure presented here reveals potential epitopes specific to the complex and indicates which peptide residues could be recognised by T-cell receptors. In addition, as the structure could be refined anisotropically, it was possible to describe the movements of the bound peptide in more detail.
Similar articles
- Identification of a MAGE-2-encoded human leukocyte antigen-A24-binding synthetic peptide that induces specific antitumor cytotoxic T lymphocytes.
Tahara K, Takesako K, Sette A, Celis E, Kitano S, Akiyoshi T. Tahara K, et al. Clin Cancer Res. 1999 Aug;5(8):2236-41. Clin Cancer Res. 1999. PMID: 10473111 - Fab antibodies capable of blocking T cells by competitive binding have the identical specificity but a higher affinity to the MHC-peptide-complex than the T cell receptor.
Neumann F, Sturm C, Hülsmeyer M, Dauth N, Guillaume P, Luescher IF, Pfreundschuh M, Held G. Neumann F, et al. Immunol Lett. 2009 Aug 15;125(2):86-92. doi: 10.1016/j.imlet.2009.06.002. Epub 2009 Jun 12. Immunol Lett. 2009. PMID: 19524620 - Characterization of a MAGE-1-derived HLA-A24 epitope-specific CTL line from a Japanese metastatic melanoma patient.
Akiyama Y, Maruyama K, Tai S, Komiyama M, Iizuka A, Takikawa M, Ohshita C, Yamamoto A, Yamazaki N, Kiyohara Y, Yamaguchi K. Akiyama Y, et al. Anticancer Res. 2009 Feb;29(2):647-55. Anticancer Res. 2009. PMID: 19331215 - The potential of melanoma antigen expression in cancer therapy.
Gillespie AM, Coleman RE. Gillespie AM, et al. Cancer Treat Rev. 1999 Aug;25(4):219-27. doi: 10.1053/ctrv.1999.0126. Cancer Treat Rev. 1999. PMID: 10448130 Review. - Outsize peptides bulge out of the groove.
Thorpe CJ. Thorpe CJ. Immunol Today. 1993 Feb;14(2):51-2. doi: 10.1016/0167-5699(93)90057-r. Immunol Today. 1993. PMID: 8447932 Review.
Cited by
- Transfer learning improves pMHC kinetic stability and immunogenicity predictions.
Fasoulis R, Rigo MM, Antunes DA, Paliouras G, Kavraki LE. Fasoulis R, et al. Immunoinformatics (Amst). 2024 Mar;13:100030. doi: 10.1016/j.immuno.2023.100030. Epub 2023 Dec 21. Immunoinformatics (Amst). 2024. PMID: 38577265 Free PMC article. - Preclinical evaluation of a novel CAR-T therapy utilizing a scFv antibody highly specific to MAGE-A4p230-239/HLA-A∗02:01 complex.
Wang L, Matsumoto M, Akahori Y, Seo N, Shirakura K, Kato T, Katsumoto Y, Miyahara Y, Shiku H. Wang L, et al. Mol Ther. 2024 Mar 6;32(3):734-748. doi: 10.1016/j.ymthe.2024.01.018. Epub 2024 Jan 18. Mol Ther. 2024. PMID: 38243600 - Structural analysis of cancer-relevant TCR-CD3 and peptide-MHC complexes by cryoEM.
Saotome K, Dudgeon D, Colotti K, Moore MJ, Jones J, Zhou Y, Rafique A, Yancopoulos GD, Murphy AJ, Lin JC, Olson WC, Franklin MC. Saotome K, et al. Nat Commun. 2023 Apr 26;14(1):2401. doi: 10.1038/s41467-023-37532-7. Nat Commun. 2023. PMID: 37100770 Free PMC article. - Structural insights into engineering a T-cell receptor targeting MAGE-A10 with higher affinity and specificity for cancer immunotherapy.
Simister PC, Border EC, Vieira JF, Pumphrey NJ. Simister PC, et al. J Immunother Cancer. 2022 Jul;10(7):e004600. doi: 10.1136/jitc-2022-004600. J Immunother Cancer. 2022. PMID: 35851311 Free PMC article. - Cytotoxic T-lymphocyte elicited therapeutic vaccine candidate targeting cancer against MAGE-A11 carcinogenic protein.
Kumar N, Sood D, Gupta A, Jha NK, Jain P, Chandra R. Kumar N, et al. Biosci Rep. 2020 Dec 23;40(12):BSR20202349. doi: 10.1042/BSR20202349. Biosci Rep. 2020. PMID: 33169789 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials